Vir Gets FDA Breakthrough Therapy Status for Two Drugs

Seeking AlphaDec 12 17:03 ET

Express News | Vir Biotechnology Inc - Phase 3 Eclipse Program to Begin in First Half of 2025

ReutersDec 12 16:05 ET

Express News | Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA Prime Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

ReutersDec 12 16:05 ET

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Vir BiotechnologyDec 12 00:00 ET

Loss-making Vir Biotechnology (NASDAQ:VIR) Has Seen Earnings and Shareholder Returns Follow the Same Downward Trajectory Over Past -80%

Simply Wall StDec 10 07:18 ET

The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA

Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.

wallstreetcnDec 8 22:05 ET